Cargando…

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs

Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs). However, intrinsic or acquired resistance remains a clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lypova, Nadiia, Dougherty, Susan M., Lanceta, Lilibeth, Chesney, Jason, Imbert-Fernandez, Yoannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307619/ https://www.ncbi.nlm.nih.gov/pubmed/34359849 http://dx.doi.org/10.3390/cells10071679

Ejemplares similares

Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq
por: Lanceta, Lilibeth, et al.
Publicado: (2021)

Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells
por: Lanceta, Lilibeth, et al.
Publicado: (2020)

Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy
por: Lypova, Nadiia, et al.
Publicado: (2019)

Simultaneous inhibition of the estrogen receptor and 6-phosphofructo-2-kinase (PFKFB3) for the treatment of ER+ breast cancer
por: Imbert-Fernandez, Yoannis, et al.
Publicado: (2014)

Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism
por: Klarer, Alden C, et al.
Publicado: (2014)

Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor
por: Chesney, Jason, et al.
Publicado: (2015)

Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib
por: Telang, Sucheta, et al.
Publicado: (2014)

Oncogenic miR-9 is a target of erlotinib in NSCLCs
por: Chen, Xi, et al.
Publicado: (2015)

Fructose-2,6-Bisphosphate synthesis by 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth
por: Chesney, Jason, et al.
Publicado: (2014)

The kinase domain of PFKFB4 is required to stimulate the glucose metabolism and growth of H460 xenografts
por: Clark, J, et al.
Publicado: (2014)

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors
por: Chesney, Jason, et al.
Publicado: (2018)

Fructose-2,6-bisphosphate links glucose to survival and growth
por: Yalcin, Abdullah, et al.
Publicado: (2014)

Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression
por: La Belle Flynn, Alyssa, et al.
Publicado: (2019)

Oxidative DNA double strand breaks and autophagy in the antitumor effect of sterically hindered platinum(II) complexes in NSCLCs
por: Chen, Feihong, et al.
Publicado: (2017)

PFKFB3 Inhibition Attenuates Oxaliplatin-Induced Autophagy and Enhances Its Cytotoxicity in Colon Cancer Cells
por: Yan, Siyuan, et al.
Publicado: (2019)

PFK15, a PFKFB3 antagonist, inhibits autophagy and proliferation in rhabdomyosarcoma cells
por: Wang, Chunhui, et al.
Publicado: (2018)

6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27
por: Yalcin, A, et al.
Publicado: (2014)

How Heme Oxygenase-1 Prevents Heme-Induced Cell Death
por: Lanceta, Lilibeth, et al.
Publicado: (2015)

Personalized post-surgical care?—possible strategies for NSCLCs with EGFR mutation
por: Suda, Kenichi
Publicado: (2020)

Silencing of PFKFB3 protects podocytes against high glucose-induced injury by inducing autophagy
por: Zhu, Zhengming, et al.
Publicado: (2021)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
por: Capalbo, Carlo, et al.
Publicado: (2019)

Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
por: Hong, Se Hyang, et al.
Publicado: (2020)

PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT
por: Shi, Wen-Kai, et al.
Publicado: (2018)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Annexin A2 Silencing Inhibits Proliferation and Epithelial-to-mesenchymal Transition through p53-Dependent Pathway in NSCLCs
por: Wu, Minhua, et al.
Publicado: (2019)

Inhibition of PFKFB3 suppresses osteoclastogenesis and prevents ovariectomy‐induced bone loss
por: Wang, Jia, et al.
Publicado: (2019)

Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach
por: Baldelli, Elisa, et al.
Publicado: (2022)

Roles of PFKFB3 in cancer
por: Shi, Linlin, et al.
Publicado: (2017)

Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer
por: Xiao, Yinan, et al.
Publicado: (2021)

Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions
por: Okabe, Seiichi, et al.
Publicado: (2022)

BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
por: Wang, Mingxing, et al.
Publicado: (2017)

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study
por: Gu, Linping, et al.
Publicado: (2022)

The PFKFB3 Inhibitor AZ67 Inhibits Angiogenesis Independently of Glycolysis Inhibition
por: Emini Veseli, Besa, et al.
Publicado: (2021)

Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth
por: Telang, Sucheta, et al.
Publicado: (2012)

Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability
por: Poels, Kikkie, et al.
Publicado: (2020)

Anti-angiogenic efficacy of 5′-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs
por: Yuan, Dongmei, et al.
Publicado: (2015)

Metastatic NSCLCs With Limited Tissues: How to Effectively Identify Driver Alterations to Guide Targeted Therapy in Chinese Patients
por: Li, Weihua, et al.
Publicado: (2021)

The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs
por: Bortolotto, Chandra, et al.
Publicado: (2023)

Inhibition of PFKFB Preserves Intestinal Barrier Function in Sepsis by Inhibiting NLRP3/GSDMD
por: Zhang, Yongsheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9pia6umvmmb0muuveoeat6anh1